دورية أكاديمية
Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy.
| العنوان: | Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy. |
|---|---|
| المؤلفون: | Martín Giménez VM; Instituto de Investigaciones en Ciencias Químicas, Facultad de Ciencias Químicas y Tecnológicas, Universidad Católica de Cuyo, San Juan 5400, Argentina., Modrego J; Laboratorio de Riesgo Cardiovascular y Microbiota, Hospital Clínico San Carlos-Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain., Gómez-Garre D; Laboratorio de Riesgo Cardiovascular y Microbiota, Hospital Clínico San Carlos-Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.; Departamento de Fisiología, Facultad de Medicina, Plaza Ramón y Cajal, s/n. Universidad Complutense, 28040 Madrid, Spain., Manucha W; Área de Farmacología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza 5500, Argentina.; Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Mendoza 5500, Argentina., de Las Heras N; Departamento de Fisiología, Facultad de Medicina, Plaza Ramón y Cajal, s/n. Universidad Complutense, 28040 Madrid, Spain. |
| المصدر: | International journal of molecular sciences [Int J Mol Sci] 2023 Jul 31; Vol. 24 (15). Date of Electronic Publication: 2023 Jul 31. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
| مستخلص: | Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients' gut microbiota, characterized by a decreased abundance of bacteria with probiotic effects. Interestingly, certain strains of these bacteria produce metabolites that can target the S protein of other coronaviruses, thereby preventing their transmission and harmful effects. At the same time, the presence of gut dysbiosis can exacerbate inflammation and oxidative stress, creating a vicious cycle that perpetuates the disease. Furthermore, it is widely recognized that the gut microbiota can metabolize various foods and drugs, producing by-products that may have either beneficial or detrimental effects. In this regard, a decrease in short-chain fatty acid (SCFA), such as acetate, propionate, and butyrate, can influence the overall inflammatory and oxidative state, affecting the prevention, treatment, or worsening of COVID-19. This review aims to explore the current evidence regarding gut dysbiosis in patients with COVID-19, its association with inflammation and oxidative stress, the molecular mechanisms involved, and the potential of gut microbiota modulation in preventing and treating SARS-CoV-2 infection. Given that gut microbiota has demonstrated high adaptability, exploring ways and strategies to maintain good intestinal health, as well as an appropriate diversity and composition of the gut microbiome, becomes crucial in the battle against COVID-19. |
| References: | PLoS One. 2021 Nov 23;16(11):e0260451. (PMID: 34813629) Biol Pharm Bull. 2019;42(9):1482-1490. (PMID: 31474709) J Med Case Rep. 2021 Feb 8;15(1):60. (PMID: 33557941) Science. 2018 Nov 16;362(6416):776-780. (PMID: 30442802) Gut. 2022 Jan;71(1):230-232. (PMID: 34230217) J Microbiol. 2021 Oct;59(10):941-948. (PMID: 34382150) J Hum Hypertens. 2021 Apr;35(4):378-380. (PMID: 32792611) Indian J Clin Biochem. 2021 Jul;36(3):266-277. (PMID: 33495676) Life Sci. 2023 Sep 15;329:121947. (PMID: 37463653) Nutrients. 2023 May 06;15(9):. (PMID: 37432351) Med Sci (Basel). 2018 Dec 14;6(4):. (PMID: 30558253) Front Cell Infect Microbiol. 2021 Nov 24;11:790422. (PMID: 34900762) Microorganisms. 2021 Apr 27;9(5):. (PMID: 33925715) Front Cell Infect Microbiol. 2020 Apr 09;10:151. (PMID: 32328469) Allergy. 2022 May;77(5):1408-1417. (PMID: 35102595) Front Microbiol. 2020 Jun 05;11:1302. (PMID: 32582134) J Dig Dis. 2023 Apr;24(4):244-261. (PMID: 37265376) Nature. 2006 Dec 21;444(7122):1027-31. (PMID: 17183312) Trends Cell Biol. 2020 Oct;30(10):805-817. (PMID: 32891490) Commun Biol. 2023 Apr 20;6(1):368. (PMID: 37081096) Med Hypotheses. 2021 Sep;154:110661. (PMID: 34385045) Microorganisms. 2020 May 23;8(5):. (PMID: 32456229) Protein J. 2020 Dec;39(6):644-656. (PMID: 33106987) Gut. 2022 Mar;71(3):544-552. (PMID: 35082169) Front Cell Infect Microbiol. 2020 Nov 26;10:576551. (PMID: 33324572) Cell. 2018 Sep 6;174(6):1388-1405.e21. (PMID: 30193112) Cell. 2012 Mar 16;148(6):1258-70. (PMID: 22424233) Med Hypotheses. 2021 Feb;147:110476. (PMID: 33482620) Front Immunol. 2021 Jan 25;11:607734. (PMID: 33569053) Front Cell Infect Microbiol. 2022 Mar 04;12:804644. (PMID: 35310853) Eur J Nutr. 2018 Feb;57(1):1-24. (PMID: 28393285) Microvasc Res. 2023 Sep;149:104557. (PMID: 37268038) Arch Med Res. 2020 Jul;51(5):384-387. (PMID: 32402576) Front Immunol. 2022 Jan 31;12:794519. (PMID: 35173707) Front Public Health. 2020 May 08;8:186. (PMID: 32574290) Nature. 2010 Mar 4;464(7285):59-65. (PMID: 20203603) Heliyon. 2023 May;9(5):e15668. (PMID: 37124341) Gut. 2020 Jun;69(6):1141-1143. (PMID: 32102928) Lett Appl Microbiol. 2020 Sep;71(3):229-234. (PMID: 32495940) Gut Microbes. 2014 May-Jun;5(3):351-6. (PMID: 24691073) Clin Immunol. 2021 May;226:108725. (PMID: 33845194) Nature. 2006 Dec 21;444(7122):1022-3. (PMID: 17183309) Therap Adv Gastroenterol. 2020 Nov 24;13:1756284820974914. (PMID: 33281941) Engineering (Beijing). 2020 Oct;6(10):1178-1184. (PMID: 33520333) mBio. 2020 Jul 23;11(4):. (PMID: 32703911) Front Cell Infect Microbiol. 2022 Apr 19;12:848650. (PMID: 35521219) Virus Res. 2020 Aug;285:198018. (PMID: 32430279) PLoS One. 2021 Mar 16;16(3):e0248730. (PMID: 33725024) Front Cell Infect Microbiol. 2020 Nov 24;10:572912. (PMID: 33330122) Indian J Microbiol. 2020 Dec;60(4):420-429. (PMID: 33012868) Front Immunol. 2023 Mar 24;14:1079277. (PMID: 37051240) Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720977715. (PMID: 33283618) J Allergy Clin Immunol. 2018 Dec;142(6):1710-1718. (PMID: 30367909) Science. 2011 Oct 7;334(6052):105-8. (PMID: 21885731) J Tradit Complement Med. 2023 Mar 13;13(2):105-106. (PMID: 36970458) J Immunol. 2017 Jan 15;198(2):564-571. (PMID: 28069751) Nat Commun. 2022 Nov 1;13(1):5926. (PMID: 36319618) Obes Med. 2020 Dec;20:100302. (PMID: 32984641) Science. 2005 Mar 25;307(5717):1915-20. (PMID: 15790844) J Inflamm Res. 2021 Nov 18;14:6025-6041. (PMID: 34819742) Int J Mol Sci. 2020 May 23;21(10):. (PMID: 32456257) Nat Rev Immunol. 2020 Jun;20(6):355-362. (PMID: 32376901) Ageing Res Rev. 2020 Sep;62:101123. (PMID: 32683039) Future Virol. 2022 Jul;:. (PMID: 35910851) Allergy. 2021 Mar;76(3):735-750. (PMID: 32762135) Gut Pathog. 2021 Dec 4;13(1):70. (PMID: 34863291) Chem Res Toxicol. 2019 Jul 15;32(7):1412-1422. (PMID: 31144504) Cell Res. 2008 Feb;18(2):290-301. (PMID: 18227861) Dig Liver Dis. 2020 Dec;52(12):1383-1389. (PMID: 33023827) Gastroenterology. 2022 Jun;162(7):2134. (PMID: 32946905) Front Microbiol. 2021 Dec 23;12:724449. (PMID: 35002992) Am J Chin Med. 2021;49(4):785-803. (PMID: 33853498) Gut. 2022 Nov;71(11):2371-2373. (PMID: 35135843) Acta Biomed. 2018 Dec 17;89(9-S):52-59. (PMID: 30561396) Clin Microbiol Infect. 2012 Jul;18 Suppl 4:2-4. (PMID: 22647038) Nutrients. 2019 Nov 22;11(12):. (PMID: 31766592) Indian J Microbiol. 2021 Mar;61(1):104-107. (PMID: 33424043) FASEB J. 2008 Aug;22(8):2880-7. (PMID: 18424768) Nature. 2012 Sep 13;489(7415):220-30. (PMID: 22972295) Turk J Gastroenterol. 2020 Oct;31(10):724-725. (PMID: 33169711) J Med Virol. 2022 Jul;94(7):2917-2918. (PMID: 35233795) Gut Microbes. 2021 Jan-Dec;13(1):1-21. (PMID: 33678150) Front Immunol. 2023 Jun 30;14:1183331. (PMID: 37457738) Dig Dis Sci. 2023 Jan;68(1):106-127. (PMID: 35503487) J Intern Med. 2022 Jun;291(6):801-812. (PMID: 35212063) J Korean Med Sci. 2023 Apr 17;38(15):e120. (PMID: 37069814) mBio. 2021 Jan 12;12(1):. (PMID: 33436436) Microorganisms. 2020 Oct 01;8(10):. (PMID: 33019592) Signal Transduct Target Ther. 2022 Apr 23;7(1):135. (PMID: 35461318) Gut Microbes. 2022 Jan-Dec;14(1):2105609. (PMID: 35915556) World J Gastroenterol. 2022 Oct 28;28(40):5801-5806. (PMID: 36353201) Microbiome. 2021 Apr 14;9(1):91. (PMID: 33853691) PLoS Biol. 2016 Aug 19;14(8):e1002533. (PMID: 27541692) Nature. 2013 Aug 29;500(7464):541-6. (PMID: 23985870) J Funct Foods. 2021 Dec;87:104850. (PMID: 34777578) Hypertension. 2020 Jul;76(1):e1-e3. (PMID: 32426999) Gastroenterology. 2020 Sep;159(3):944-955.e8. (PMID: 32442562) ACS Nano. 2020 May 26;14(5):5179-5182. (PMID: 32356654) J Nutr Biochem. 2022 Nov;109:109102. (PMID: 35817244) Nature. 2011 May 12;473(7346):174-80. (PMID: 21508958) J Gastroenterol Hepatol. 2022 May;37(5):823-831. (PMID: 35170078) Nutrients. 2022 Jan 14;14(2):. (PMID: 35057534) Gut. 2021 Apr;70(4):698-706. (PMID: 33431578) Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937170. (PMID: 32600125) Therap Adv Gastroenterol. 2021 Aug 04;14:17562848211035670. (PMID: 34394726) Clin Gastroenterol Hepatol. 2012 Oct;10(10):1096-100. (PMID: 22902773) Cell Mol Gastroenterol Hepatol. 2018 May 29;6(3):370-388.e3. (PMID: 30182050) Arch Virol. 2021 Jul;166(7):1819-1840. (PMID: 33745067) Nutrients. 2020 May 27;12(6):. (PMID: 32471251) Probiotics Antimicrob Proteins. 2021 Aug;13(4):1138-1156. (PMID: 33537958) Clin Immunol. 2020 Sep;218:108542. (PMID: 32663514) Am J Physiol Lung Cell Mol Physiol. 2020 Dec 1;319(6):L941-L948. (PMID: 32996774) Gut. 2022 Jun;71(6):1106-1116. (PMID: 35140064) Microorganisms. 2023 Feb 10;11(2):. (PMID: 36838417) SAGE Open Med. 2021 Feb 01;9:2050312121991246. (PMID: 33614035) Microb Pathog. 2022 Dec;173(Pt A):105798. (PMID: 36174833) Trends Food Sci Technol. 2021 Feb;108:187-196. (PMID: 33519087) Nutrients. 2023 Jan 17;15(3):. (PMID: 36771194) Phys Act Nutr. 2021 Jun;25(2):1-7. (PMID: 34315200) |
| معلومات مُعتمدة: | PI22/01608; 2020 Seria A 4000 FIS, FEDER, FONCyT |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; gut microbiota; immune system; inflammation; probiotics |
| تواريخ الأحداث: | Date Created: 20230812 Latest Revision: 20230814 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10419057 |
| DOI: | 10.3390/ijms241512249 |
| PMID: | 37569625 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1422-0067 |
|---|---|
| DOI: | 10.3390/ijms241512249 |